1. Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma

   • Murali Kesavan
   • Toby A. Eyre
   • Graham P. Collins

   B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) Open access 29 June 2019 Pages: 207 - 218

   

2. Targeting Translation of mRNA as a Therapeutic Strategy in Cancer

   • Ipsita Pal
   • Maryam Safari
   • Changchun Deng

   B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 24 June 2019 Pages: 219 - 227

   

3. Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly

   • Yasir Khan
   • Elizabeth A. Brem

   B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 21 June 2019 Pages: 228 - 238

   

4. Mantle Cell Lymphoma: Which Patients Should We Transplant?

   • James N. Gerson
   • Stefan K. Barta

   B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 19 June 2019 Pages: 239 - 246

   

5. Pathogen-Specific T Cells Beyond CMV, EBV and Adenovirus

   • Wei Jiang
   • Barbara Withers
   • Emily Blyth

   CART and Immunotherapy (M Ruella and P Hanley, Section Editors) 21 June 2019 Pages: 247 - 260

6. Induced Pluripotent Stem Cell (iPSC)–Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges

   • Alexandros Nianias
   • Maria Themeli

   CART and Immunotherapy (M Ruella and P Hanley, Section Editors) Open access 26 June 2019 Pages: 261 - 268

   

7. Overcoming Challenges in Process Development of Cellular Therapies

   • Steven L. Highfill
   • David F. Stroncek

   CART and Immunotherapy (M Ruella and P Hanley, Section Editors) 06 July 2019 Pages: 269 - 277

8. Towards Automated Manufacturing for Cell Therapies

   • David Smith
   • Thomas R. J. Heathman
   • Brian Hampson

   CART and Immunotherapy (M Ruella and P Hanley, Section Editors) 28 June 2019 Pages: 278 - 285

   

9. Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era

   • Gerald P. Linette
   • Beatriz M. Carreno

   CART and Immunotherapy (M Ruella and P Hanley, Section Editors) 11 June 2019 Pages: 286 - 291

10. Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia

    • Krish Patel
    • John M. Pagel

    Chronic Lymphocytic Leukemias (N Jain, Section Editor) 15 June 2019 Pages: 292 - 301

11. Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL

    • Adam S. Kittai
    • Matthew Lunning
    • Alexey V. Danilov

    Chronic Lymphocytic Leukemias (N Jain, Section Editor) 02 May 2019 Pages: 302 - 309

12. The Rationale for Immunotherapy in Myeloproliferative Neoplasms

    • Lucia Masarova
    • Prithviraj Bose
    • Srdan Verstovsek

    Myeloproliferative Neoplasms (B Stein, Section Editor) 21 June 2019 Pages: 310 - 327

13. Emerging Role of Integrative Medicine in Hematologic Malignancies: a Literature Review and Update on Current Trends in Complementary Medical Practices in Hematologic Cancers

    • Onyemaechi N. Okolo
    • Krisstina Gowin

    Health Economics (N Khera, Section Editor) 18 June 2019 Pages: 328 - 336

14. Is There a Role for Dose Modification of TKI Therapy in CML?

    • M. Copland

    Chronic Myeloid Leukemias (M Mauro, Section Editor) Open access 14 June 2019 Pages: 337 - 345

15. Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS

    • Rami S. Komrokji

    Myelodysplastic Syndromes (M Savona, Section Editor) 15 June 2019 Pages: 346 - 351